Magnetic resonance imaging at 1.5 T with immunospecific contrast agent in vitro and in vivo in a xenotransplant model
- 12 December 2006
- journal article
- Published by Springer Science and Business Media LLC in Magnetic Resonance Materials in Physics, Biology and Medicine
- Vol. 19 (6), 313-320
- https://doi.org/10.1007/s10334-006-0059-6
Abstract
Object: Demonstrating the feasibility of magnetic resonance imaging (MRI) at 1.5 T of ultrasmall particle iron oxide (USPIO)-antibody bound to tumor cells in vitro and in a murine xenotransplant model. Methods: Human D430B cells or Raji Burkitt lymphoma cells were incubated in vitro with different amounts of commercially available USPIO-anti-CD20 antibodies and cell pellets were stratified in a test tube. For in vivo studies, D430B cells and Raji lymphoma cells were inoculated subcutaneously in immunodeficient mice. MRI at 1.5 T was performed with T1-weighted three-dimensional fast field echo sequences (17/4.6/13°) and T2-weighted three-dimensional fast-field echo sequences (50/12/7°). For in vivo studies MRI was performed before and 24 h after USPIO-anti-CD20 administration. Results: USPIO-anti-CD20-treated D430B cells, showed a dose-dependent decrease in signal intensity (SI) on T2*-weighted images and SI enhancement on T1-weighted images in vitro. Raji cells showed lower SI changes, in accordance to the fivefold lower expression of CD20 on Raji with respect to D430B cells. In vivo 24 h after USPIO-anti-CD20 administration, both tumors showed an inhomogeneous decrease of SI on T2*-weighted images and SI enhancement on T1-weighted images. Conclusions: MRI at 1.5 T is able to detect USPIO-antibody conjugates targeting a tumor-associated antigen in vitro and in vivo.Keywords
This publication has 15 references indexed in Scilit:
- The Progress and Promise of Molecular Imaging Probes in Oncologic Drug DevelopmentClinical Cancer Research, 2005
- First‐pass contrast‐enhanced magnetic resonance angiography in humans using ferumoxytol, a novel ultrasmall superparamagnetic iron oxide (USPIO)‐based blood pool agentJournal of Magnetic Resonance Imaging, 2004
- A human antibody that promotes remyelination enters the CNS and decreases lesion load as detected by T2‐weighted spinal cord MRI in a virus‐induced murine model of MSThe FASEB Journal, 2004
- Magnetic resonance tracking of transplanted bone marrow and embryonic stem cells labeled by iron oxide nanoparticles in rat brain and spinal cordJournal of Neuroscience Research, 2004
- In vivo magnetic resonance imaging of immune cells in the central nervous system with superparamagnetic antibodiesThe FASEB Journal, 2003
- Assessing contrast on MR images.Radiology, 1997
- Surface properties of superparamagnetic iron oxide MR contrast agents: Ferumoxides, ferumoxtran, ferumoxsilMagnetic Resonance Imaging, 1995
- Liver MR imaging with iron oxides: toward consensus and clinical practice.Radiology, 1994
- Dual contrast enhancement of both T1- and T2-weighted sequences using ultrasmall superparamagnetic iron oxideMagnetic Resonance Imaging, 1993
- Iron oxide-enhanced MR imaging of the liver and spleen: review of the first 5 years.American Journal of Roentgenology, 1990